An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants

Stopped early

Conditions studied: Multiple Myeloma

In brief

The purpose of this study is to describe contemporary, real-world patterns of participant characteristics, clinical disease presentation, therapeutic regimen chosen, and clinical outcomes in participants with newly diagnosed \[ND\] multiple myeloma (MM) and participants with relapsed/refractory \[R/R\] MM.

Key facts

Study ID

NCT02761187

Run by

Takeda

People needed

4253

Starts

2016-07-01

Expected to finish

2021-09-30

Last updated by the study team

2025-02-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Is 18 years of age or older.
• Is experiencing the following:
• Newly diagnosed MM within 3 months from initiation of treatment with documented month and year of diagnosis, criteria met for diagnosis, stage, and MM-directed treatment history, including duration, or
• Relapsed/refractory MM who have received 1 to 3 prior lines of therapy with documented data in the medical record regarding diagnosis (month and year), the regimens used in 1st, 2nd, and 3rd line as applicable, whether stem cell transplant was part of 1st, 2nd, and 3rd line of therapy, whether consolidation/maintenance was part of 1st, 2nd, and 3rd line of therapy, also whether investigational therapy/treated on a clinical trial was part of any of these regimens.
• Is willing and able to sign informed consent to participate. Is willing and able to complete patient-reported outcomes (PROs) in accordance with local regulatory and data protection requirements.

You may not qualify if…

• Is reporting to a site in this study for a second opinion (consultation only) or participants whose frequency of consult and follow-up are not adequate for quarterly electronic case report form (eCRF) completion.
• Has participated in another study (observational or interventional) that prohibits participation in this study.

Where it is running

• University of Arkansas For Medical Sciences — Little Rock, Arkansas, United States
• University of California San Diego — La Jolla, California, United States
• St Joseph Heritage Healthcare — Santa Rosa, California, United States
• Rocky Mountain Cancer Centers (Williams) - USOR — Denver, Colorado, United States
• Poudre Valley Health System — Fort Collins, Colorado, United States
• George Washington University — Washington D.C., District of Columbia, United States
• SCRI Florida Cancer Specialists East — Daytona Beach, Florida, United States
• SCRI Florida Cancer Specialists South — Fort Myers, Florida, United States
• SCRI Florida Cancer Specialists North — St. Petersburg, Florida, United States
• Illinois Cancer Specialists (Niles) - USOR — Niles, Illinois, United States
• Indiana University — Indianapolis, Indiana, United States
• East Jefferson General Hospital — Metairie, Louisiana, United States
• Central Maine Medical Center — Lewiston, Maine, United States
• Maryland Oncology Hematology (Columbia) - USOR — Columbia, Maryland, United States
• Barbara Ann Karmanos Cancer Center — Detroit, Michigan, United States
• Park Nicollet Institute — Saint Louis Park, Minnesota, United States
• Central Care Cancer Center — Bolivar, Missouri, United States
• Kansas City VA Medical Center — Kansas City, Missouri, United States
• Washington University in St. Louis — St Louis, Missouri, United States
• Hunterdon Hematology Oncology — Flemington, New Jersey, United States
• San Juan Oncology Associates — Farmington, New Mexico, United States
• Saint Francis Hospital — East Hills, New York, United States
• Mount Sinai Medical Center — New York, New York, United States
• Levine Cancer Center — Charlotte, North Carolina, United States
• CARTI Cancer Center — Little Rock, Arkansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.